Infliximab Uses, Side Effects & Warnings - Drugs

  1. Infliximab side effects. Get emergency medical help if you have signs of an allergic reaction: hives; chest pain, difficult breathing; fever, chills, severe dizziness; swelling of your face, lips, tongue, or throat.. Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, light-headed, itchy or tingly, short of breath, or have a headache, fever.
  2. Infliximab is a common treatment for people with Crohn's Disease and Ulcerative Colitis. Our information can help you to decide if this treatment is right for you. It looks at: ~ how the medicine works ~ what you can expect from the treatment ~ possible side effects ~ stopping or changing treatment Starting infliximab may change your risk.
  3. Infliximab is a type of drug known as a biological therapy. It can be prescribed for: rheumatoid arthritis; psoriatic arthritis; axial spondyloarthritis, including ankylosing spondylitis.; In some cases, doctors may prescribe infliximab to treat certain types of vasculitis.. The immune system normally works to protect the body from infections
  4. Infliximab injectable solution is a prescription medication that's used to treat arthritis, ulcerative colitis, and other inflammatory diseases. It's available only as the brand-name drugs.

Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions 3. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in. Infliximab is an antibody administered intravenously that is used for treating several chronic inflammatory diseases. Infliximab works by blocking the effects of tumor necrosis factor alpha (TNF alpha), a substance made by cells of the body which has an important role in promoting inflammation. There are two other injectable drugs that block TNF alpha--adalimumab and etanercept () For infliximab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery, then continued 48 hours' postpartum (Mahadevan 2019). Infliximab may be continued during the first and second trimesters of pregnancy in females with rheumatic and musculoskeletal diseases REMICADE ® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections which include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body or caused infections in certain areas.

Infliximab ist ein chimärer monoklonaler Antikörper gegen den Tumornekrosefaktor α (TNFα), der als Immunsuppressivum eingesetzt wird. 2 Indikationen. Die Hauptindikation stellt der Morbus Crohn dar 2 1. NAME OF THE MEDICINAL PRODUCT Remicade 100mg powder for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 100mg of infliximab.Infliximab is a chimeric human-murine IgG1monoclona

Infliximab is a monoclonal antibody which neutralises TNF-alpha in humans. It was studied in a randomised controlled trial of 108 patients with moderate to severe Crohn's disease. Four weeks after a single infusion, 65% of the patients given infliximab had a clinical response compared with only 17% of the patients given a placebo Allow the reconstituted solution to stand for 5 minutes. Visually inspect the reconstituted solution for particulate matter and discoloration. The reconstituted solution should be colorless to light yellow and opalescent, and the solution may develop a few translucent particles as infliximab is a protein

Infliximab se ha asociado con reacciones agudas relacionadas con la perfusión, que incluyen shock anafiláctico y reacciones de hipersensibilidad retardada (ver sección 4.8). Pueden aparecer reacciones agudas a la perfusión, entre ellas reacciones anafilácticas durante la perfusión (en segundos) o a las pocas horas después de la perfusión Infliximab and adalimumab for Crohn's disease (May 2010) Recommended with restrictions. NICE TA195 Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) Recommended with restrictions. NICE TA19 Infliximab works by blocking the actions of a certain natural substance (tumor necrosis factor alpha) in the body. This helps to decrease swelling (inflammation) and weaken your immune system, which slows or stops the damage from the disease.This monograph is about the following infliximab products: infliximab, infliximab-abda, infliximab-axxq. The more common side effects with infliximab products are respiratory infections (that may include sinus infections and sore throat), headache, rash, coughing, and stomach pain. What is RENFLEXIS? RENFLEXIS ® (infliximab-abda) is a prescription medication used to treat: Crohn's Diseas

Infliximab gis som en intravenøs infusjon. Dosen bestemmes av legen. Vanlig dose av infliximab er 3 - 5 mg/kg kroppsvekt gitt i uke 0, 2 og 6, deretter hver 8. uke. Ved utilstrekkelig effekt kan det eventuelt vurderes å øke dosen. Legen avgjør hvilken infliximab (Remsima, Inflectra, Remicade, Flixabi eller Zessly) du skal bruke

Infliximab Crohn's & Colitis U

ASPIRE (Active-controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset): a 54-week, multicenter, double-blind, active treatment-controlled, randomized, phase 3 study of REMICADE® with methotrexate (MTX) in 1004 MTX-naïve adult patients with moderately to severely active early RA (≥ 3 months. Symptoms of an infusion reaction that may occur during infliximab treatment include pain/swelling at the injection site, shortness of breath, flushing, chills, fever, headache, and rash. If you. Wat is infliximab? Infliximab wordt gebruikt bij de behandeling van verschillende auto-immuunziekten. Hierdoor nemen pijn, zwelling en stijfheid van de gewrichten af waardoor op de langere termijn de kans op gewrichtsschade afneemt. Infliximab wordt toegediend via een infuus op de dagbehandeling. lees meer (infliximab-dyyb) and Avsola ™ (infliximab-axxq) are the preferred infliximab products. Coverage will be provided for Inflectra ® ™or Avsola contingent on the coverage criteria in the . Diagnosis -Specifci Criteria. section. Coverage for Renflexis ® (infliximab-abda), ®Remicade (infliximab), or other non -preferred infilximab product. Infliximab. Infliximab (IFX) is a TNF-α inhibitor and full IgG1-antibody which is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. From: Drugs During Pregnancy and Lactation (Third Edition.

Infliximab is a chimeric tumor necrosis factor-alpha (TNF-α) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection Infliximab tem demonstrado melhorar a função física em doentes com artrite psoriática e reduzir a taxa de progressão da lesão ao nível da articulação periférica de acordo com a avaliação por raio-X em doentes com subtipos simétricos poliarticulares da doença (ver secção 5.1) Infliximab. Embarazo. Estudios en animales no han revelado daño fetal, sin embargo no hay estudios bien controlados en mujeres embarazadas. O bien, estudios en animales han mostrado efectos adversos fetales, pero estudios en mujeres embarazadas no han mostrado riesgo fetal. Sólo debe utilizarse en el embarazo si es claramente necesario

A la semana 16 se inició infliximab con los pacientes del grupo placebo, subsecuentemente todos los pacientes recibieron 5 mg/kg de infliximab cada 8 semanas hasta la semana 46. El tratamiento con infliximab se asoció con mejoría de los signos y síntomas evaluados mediante criterios de ACR Infliximab is sometimes known by the brand name 'Remicade'. Why am I being treated with this medicine? Infliximab is used to treat severe active Crohn's Disease and active fistulising Crohn's Disease in adults and in children/young people aged 6 -17 years. It may be given to yo REMICADE (infliximab) Lyophilized Concentrate for Injection, for Intravenous Use . Initial U.S. Approval: 1998 . WARNING: SERIOUS INFECTIONS and MALIGNANCY. See full prescribing information for complete boxed warning . SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization o Product Name : Remsima ® / U.S. Product Name : Inflectra ® INN : Infliximab Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn's disease(CD), Psoriatic Arthritis(PsA), Psoriasis(PsO) Protein Type : Monoclonal antibody (mAb) Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is. Infliximab ist ein chimärer monoklonaler Antikörper.Infliximab ist gegen den Tumor-Nekrose-Faktor α (TNFα) gerichtet und wird daher auch als TNF-Blocker bezeichnet.. TNFα ist bei Erkrankungen des rheumatoiden Formenkreises von zentraler Bedeutung, er beeinflusst eine Vielzahl von Signalsystemen des Immunsystems

Infliximab neutraliza a actividade biológica do TNFa através da ligação com elevada afinidade para as formas solúveis e transmembranares de TNF-a e inibe a ligação de TNFa com os seus receptores. Infliximab não neutraliza TNFB (linfotoxina a), uma citoquina relacionada que utiliza os mesmos receptores que TNFa L'infliximab (nome commerciale Remicade) è un anticorpo monoclonale chimerico contro il fattore di necrosi tumorale usato come farmaco per trattare le malattie autoimmuni. Infliximab è stato approvato dalla Food and Drug Administration (FDA) per il trattamento della psoriasi, la malattia di Crohn, la spondilite anchilosante, artrite psoriasica, artrite reumatoide e la colite ulcerosa Infliximab je chimérická monoklonální protilátka namířená proti prozánětlivému cytokinu TNF-α (tumor nekrotizujícímu faktoru α). Pod obchodním názvem Remicade, Inflectra, Remsima nebo Flixabi je indikován k léčbě revmatoidní artritidy, Crohnovy nemoci, ulcerózní kolitidy nebo Bechtěrevově nemoci. Zavedení infliximabu do klinické praxe zlepšilo kvalitu života. Infliximab ist ein antiinflammatorischer und selektiv immunsupprimierender Wirkstoff, der vor allem zur Behandlung von Morbus Crohn und rheumatoider Arthritis angewendet wird. Infliximab gehört als chimärer, human-muriner monoklonaler IgG1K-Antikörper zur pharmakotherapeutischen Gruppe der TNF-alpha-Inhibitoren, monoklonale IgG1-Antikörper. Infliximab è stato sviluppato per legarsi a un messaggero chimico presente nell'organismo denominato fattore di necrosi tumorale alfa (TNF-alfa). Questo messaggero contribuisce a causare l'infiammazione e si riscontra in elevate quantità nei pazienti affetti dalle malattie per trattare le quali è indicato Remicade

Infliximab Side-effects, uses, time to wor

Infliximab is een zogenaamde biological. Dit betekent dat het door levende cellen in celkweken wordt gemaakt. Artsen schrijven het voor bij reumatoïde artritis, de ziekte van Bechterew, psoriasis en bij de chronische darmziekten ziekte van Crohn en colitis ulcerosa. Het wordt soms gebruikt bij oogontsteking binnen in het oog (uveïtis) en bij. Az infliximab termék a fázis I. és a fázis III. vizsgálatokban az originális termékkel (Remicade) egyenértékűséget mutatott a Bechterew-kór kezelésében. A közlemény szerint az eredmények meggyőzően igazolják a biohasonló készítmény minőségét, biztonságosságát és hatékonyságát, amelynek forgalomba hozatali. Der Wirkstoff Infliximab ist ein Antikörper, der einen zentralen Entzündungsbotenstoff im Körper (Tumornekrosefaktor alpha = TNF) abfangen kann und so antientzündlich wirkt. Er wird bei schweren Autoimmunerkrankungen eingesetzt und muss, da er ein biotechnologisch hergestelltes Eiweiß ist, direkt als Infusion verabreicht werden • Infliximab is a chimeric anti-tumour necrosis factor antibody approved by the Therapeutic Goods Administration (TGA) for use in Fistulising Crohn's Disease, Refractory Luminal Crohn's disease, Moderate/Severe Ulcerative Colitis and Acute Severe Colitis. Prescribing is restricted to Gastroenterologists for

Infliximab: Side Effects, Dosage, Uses, and Mor

Infliximab är en monoklonal antikropp - en typ av protein som binder till ett specifikt mål i kroppen som kallas för TNF alfa ( tumörnekrosfaktor alfa). Remicade tillhör en grupp läkemedel som kallas TNF-hämmare. Det används hos vuxna vid följande inflammatoriska sjukdomar: Reumatoid artrit. Psoriasisartrit Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset. Anaphylaxis, urticaria, dyspnea, and hypotension have occurred in association with infusions of infliximab products. Medications for the treatment of hypersensitivity reactions should be available L'infliximab (Remicade®, Inflectra®, Remsisma®, Flixabi®) agit en inhibant une protéine produite en excès au cours de la maladie de Crohn, le TNFα. Le TNFα est produit par les cellules de l'organisme et favorise l'inflammation, en participant à la lutte contre certaines infections. L'infliximab est un anticorps monoclonal, c. Se liste over medicin, der indeholder Infliximab. Om medicin.dk - professionel Medicin.dk - professionel er en del af Medicin.dk. Medicin.dk leverer information om medicin, sygdom og behandling til hele Danmark

Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ). Pharmacodynamic effects. Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays. Infliximab prevented disease in transgenic mice that. Anti-infliximab IgE antibodies were not found, and the anti-infliximab antibodies did not cross react with adalimumab. One week after the anaphylactoid reaction to infliximab, adalimumab therapy was initiated. Twelve days after the first adalimumab administration (80 mg), a delayed hypersensitivity reaction occurred Infliximab ist ein chimärer, human-muriner, monoklonaler IgG1-Antikörper, der mittels rekombinanter DNA-Technologie in murinen Hybridomzellen hergestellt wird. Nach Rekonstitution enthält jeder ml 10 mg Infliximab. Vollständige Auflistung der sonstigen Be Infliximab appears to be an effective, safe treatment for patients with refractory sarcoidosis, including such manifestations as lupus pernio, uveitis, hepatic sarcoidosis, and neurosarcoidosis. Infliximab appears to be steroid sparing. Patients receiving the drug should be screened for latent tuber Clinical Gastroenterology and HepatologyVol. 15Issue 8. Preview. This study compares the effectiveness and safety of infliximab and adalimumab in biologic-naive patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched cohort study. Full-Text

Infliximab: Uses, Interactions, Mechanism of Action

El infliximab es un anticuerpo monoclonal con potente acción antiinflamatoria. Fundamentalmente, hace dos cosas. Por una parte, disminuye el efecto del factor de necrosis tumoral, que es una citocina que producen diversas células de nuestro cuerpo y que aumenta los síntomas inflamatorios. Por otra, induce la apoptosis (muerte celular) de linfocitos que se encuentran anormalmente activados infliximab 2 Australian Rheumatology Association Revised July 2017 Stopping infliximab If infliximab treatment is stopped or not received at the recommended intervals there is a risk that your condition may worsen. Continue with your treatment unless advised by your specialist/GP or unless side effects develop (see Side effects) Call +91-8043052166. Contact Supplier Request a quote. Remicade 100 Mg Infliximab Injection ₹ 32,000/ Vial. Get Quote. INFIMAB Injection Infliximab 100 mg, Sun Pharma, Prescription. ₹ 32,000/ Vial Get Latest Price. Packaging Size: 1 powder for injection in 1 vial. Brand: INFIMAB Injection. Manufacturer: Sun Pharma DESCRIPTION. Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps.

infliximab (Remicade): TNF Inhibitor Uses, Side Effects

特集:インフリキシマブ(Infliximab, Remicade) | インフリキシマブとは?Infliximab(商標名Remicade)は、腫瘍壊死因子α(TNF-α)に対して作用するマウス-ヒトキメラモノクローナル抗体です。リウマチ性疾患、自己免疫疾患の治療に使用されています。I The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only adalimumab and infliximab have been found to be efficacious in Crohn's disease. The present studies evaluated the TNF-bin Infliximab is now commonly used in patients with IBD to achieve and maintain clinical response and remission. Predicting long-term outcome of infliximab therapy could improve effectiveness and decrease the risk of adverse events during maintenance phase of treatment. However, despite the fact that several potential predictors were identified in. Submitted by: Phung Quan Infliximab is an IgG monoclonal antibody, meaning it is derived from B cells that clonally express copies of a heavy chain and light chain which are linked covalently to form a unique antibody molecule. With this structure, infliximab binds strongly to circulating and membrane-bound TNF-α ligands in order to inhibit the action of TNF-α1

Infliximab injection products come as a powder to be mixed with sterile water and administered intravenously (into a vein) by a doctor or nurse. It is usually given in a doctor's office once every 2 to 8 weeks, more often in the beginning of your treatment and less often as your treatment continues Infliximab, a monoclonal antibody to tumour necrosis factor (TNF) α, is an important advance in the treatment of Crohn's disease. 1- 5 The efficacy of infliximab for the treatment of ulcerative colitis is still unclear. 6, 7 Infliximab was approved for the treatment of Crohn's disease in 1998 based on a 12 week phase 2 trial in 108 patients 1 (followed by a 36 week extension trial) 3. Infliximab is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and severe or disabling plaque psoriasis in adults. Infliximab is also used to treat ulcerative colitis or Crohn's disease in adults and children at least 6 years old. Infliximab is often used when other medicines have.. Infliximab, a tumor necrosis factor (TNF) blocker, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab is produced by a recombinant murine myeloma cell line, SP2/0

InFLIXimab (Professional Patient Advice) - Drugs

Infliximab is proven for the treatment of ankylosing spondylitiswhen all of the following criteria is met: 1,57, 62. For initial therapy, all of the following: o Diagnosis of ankylosing spondylitis (AS); and o Infliximab is dosed according to U.S. Food and Drug Administration (FDA) labeled dosing for ankylosing spondylitis; an Infliximab Level and Anti-drug Antibody for IBD - When treatment of inflammatory bowel disease with infliximab or its biosimilar fails, a physician may need to consider treatment options, such as adjusting dose or dosing intervals, switching to a different TNF blocker, or switching to a non-TNF blocker. This test (1) measures infliximab and infliximab-dyyb (inflectra) levels to help.

Infliximab therapy resulted in prompt resolution of the inflammatory reaction and retinal exudation, with improvement in VA, that was subsequently maintained with maintenance therapy. The intravenous infliximab infusions were scheduled at 0, 4, 8, and 12 weeks initially, and every 2 months thereafter.. Infliximab and Infliximab-abda are TNFα inhibitors currently FDA-approved for the treatment of autoimmune disorders, including Crohn's disease and rheumatoid arthritis. The risks and adverse reactions are described in the approved prescribing information for infliximab (or infliximab-abda). Infliximab will be used when available

Official Consumer Website for REMICADE® (infliximab

Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and seroconversion rates in infliximab-treated patients (n. Infliximab darf bei Kindern und Jugendlichen eingesetzt werden. Allerdings nur bei chronisch-entzündlichen Darmerkrankungen wie Morbus Crohn und Colitis ulerosa und aufgrund fehlender Daten auch erst ab dem 6. Lebensjahr. Kinder sollten möglichst vor Beginn einer Therapie mit Infliximab alle Impfungen nach Vorgaben der STIKO erhalten haben Mechanism of action. Infliximab works by blocking the functional activity of a cell-signaling protein (cytokine) called tumor necrosis factor alpha (TNF-α), which is a substance that plays a key. Infliximab stop timing <4 weeks and 4 to 8 weeks prior to surgery were associated with similar rates of serious infection at 30 days and prosthetic joint infection at 1 year compared with infliximab stop timing 8 to 12 weeks. In contrast, administering glucocorticoids at dosages higher than 10 mg/d more than doubled the risk for 30-day. Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. The Matriks Biotek shikari Antibody to Infliximab ELISA Kit can be efficiently used for monitoring.

Infliximab - DocCheck Flexiko

Infliksymab, infliksimab (łac. infliximabum) - chimeryczne ludzko-mysie przeciwciało monoklonalne klasy IgG1, wiążące się z dużym powinowactwem zarówno z rozpuszczalną, jak i transbłonową formą ludzkiego czynnika martwicy nowotworów TNF-alfa (tumour necrosis factor).Infliksymab tworzy in vivo stabilne kompleksy z ludzkim TNF-alfa, co jest równoznaczne z utratą aktywności. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Robert J Brogan, 1 Despina Eleftheriou, 1 James Gnanapragasam, 2 Nigel J Klein, 3 and Paul A Brogan 1 Author. Infliximab è un anticorpo chimerico, umano-murino, monoclonale, che si lega con alta affinità sia alla forma solubile che a quella transmembrana del TNFα, ma non alla linfotossina α (TNFβ). Effetti farmacodinamici. Infliximab inibisce in vitro l'attività del TNFα in un'ampia varietà di saggi biologici in vitro. Infliximab preveniva.

The presence of infliximab drug, even at concentrations well above target treatment levels (>50 ug/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rhematoid arthritis, or. Infliximab (Remicade ® ) The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary. Infliximab, a monoclonal antibody tumor necrosis factor-alpha inhibitor, is an effective therapy that is indicated for the treatment of patients with Crohn's disease. Although dose escalation from 5 mg/kg to 10 mg/kg is allowed according to the prescribing. Infliximab, an intravenously administered chimeric anti-TNF antibody, was originally approved for use in inflammatory bowel diseases (IBD) in 1998. More recently, an infliximab biosimilar molecule, CT-P13, was approved for the same indications, with a similar efficacy and safety profile as the originator molecule. Impact of TNF neutralization by infliximab on the course of IL-6 (a) and lymphocytes (b) in severe COVID-19. Gray bar and dotted lines indicate Q1 and Q3 and median of 15 contemporary control patients, respectively. Solid lines indicate the individual course of seven patients treated with infliximab

IJMS | Free Full-Text | The Anti-TNF-α Antibody InfliximabPsoriasis - WikEM

Infliximab is an injectable solution used to treat rheumatoid arthritis, ankylosing sponylitis, and psoriatic arthritis Infliximab is one of a group of anti-inflammatory agents that work by blocking the action of the pro-inflammatory cytokine, Tumour Necrosis Factor-alpha (TNF-α). TNF-α is a signalling protein that increases the activity of cells involved in inflammation. Infliximab stops TNF-α from binding to cells, thereby reducing inflammation 1 of 4 alternatives. Calms down your immune system. Remicade (infliximab) is an effective treatment for many autoimmune diseases, but you can have serious side effects. Calms the immune system and prevents joint damage. Cimzia (certolizumab) effectively calms down your immune system, but you have to be comfortable receiving injections